Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations By Ogkologos - October 22, 2025 176 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma 2026 ESMO Breast Cancer Award Recipient Announced Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type MOST POPULAR Artificial Intelligence May Aid in the Discrimination of Radiation Pneumonitis from... March 24, 2021 England slips further off-track for smokefree 2030 target December 29, 2022 Coronavirus y COVID-19: Qué deben saber las personas con cáncer June 24, 2020 Cauliflower Rice August 28, 2020 Load more HOT NEWS FDA Grants Accelerated Approval to Tucatinib with Trastuzumab for Colorectal Cancer When Ellen Found Out There Was A Grieving Mother In The... Embrace Your Inner Flexibility Higher Risk of Invasive Behaviour for Oncogenic Fusions–Driven Paediatric Thyroid Cancers
